<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335318">
  <stage>Registered</stage>
  <submitdate>8/04/2010</submitdate>
  <approvaldate>13/04/2010</approvaldate>
  <actrnumber>ACTRN12610000293066</actrnumber>
  <trial_identification>
    <studytitle>The LoDoCo Trial: The effect of low dose colchicine on the natural history of patients with stable coronary artery disease</studytitle>
    <scientifictitle>The LoDoCo Trial: The effect of low dose colchicine on the natural history of patients with stable coronary artery disease</scientifictitle>
    <utrn>U1111-1114-5895</utrn>
    <trialacronym>LoDoCo Study</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary artery disease</healthcondition>
    <healthcondition>Acute ischemic coronary events</healthcondition>
    <healthcondition>Acute ischemic cerebrovascular events</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Colchicine 0.5mg/day orally for duration of study period unless side effects occur [minimum of 2 years]</interventions>
    <comparator>No colchicine</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite of: Major Adverse Cardiac or Cerebrovascular Events [MACCE] including [a] Acute coronary sydromes as evidenced by a history of ischemic chest pain, changes in the electrocardiogram and a rise in serum Troponin above the normal range [b] Unstable [new or worsening] angina associated with a documented change in coronary anatomy as evidenced by repeat angiography [c] Sudden Cardiac Death as evidenced by the death certificate or non-fatal out of hospital cardiac arrest [d] New [documented] stroke unrelated to atrial fibrillation or intra-cranial hemorrhage as evidenced by a diagnostic change on cerebral tomography [CT] or magnetic resonant imaging [MRI] of the brain AND after review of the patient and all relevant data by an independent specialist neurologist]</outcome>
      <timepoint>The final analysis will occur once the last patient enrolled to the study has been followed for 2 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tolerability to therapy as evidenced by the patients self reporting of side-effects and willingness to continue therapy.</outcome>
      <timepoint>Intolerance will be considered as being 'early' if the patient chooses to cease treatment due to percieved side effect within 1 month of starting treatment, and 'late' if side-effects begin after that time</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Angiographic proof of coronary disease
Clinically stable for &gt;6months
Coronary Artery Bypass Grafting [CABG] more than 10 years ago or CABG at any time if the patient had subesquently had recurrent angina and angiographic evidence of blocked grafts or progressive native coronary disease requiring intervention with angioplasty 
Willing to be randomised
Likely to be compliant</inclusivecriteria>
    <inclusiveminage>35</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Any clinically significant co-morbidity
Clinical instability within prior 6 months  CABG&lt;10 years ago unless intervention has been required
Unwilling to enrole or uncertainty re compliance
Already on long-term colchicine for unrelated condition
Known sensitivity to colchicine
Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Patients attending out-patient cardiology clinic are told about the study and asked to enter the trial. If they agree the patients information and signed consent form are forwarded to an independent person who then enters the patients clinical details into the study data bases in a sequential manner.

The first column of the data base has a random seqence of '1' or '0' indicating whether the patient will [1] or will not [0] recience therapy. 

Hence the treating Cardiologist is blinded to the randomisation sequence at the time the patient is recruited into the study</concealment>
    <sequence>A randomization sequence was generated by computer and held by an independent 3rd party and remained concealed form the referring Cardiologists</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Additional patients will be randomized to replace patients who cease the study drug within 30 days because of intolerance to treatment</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/09/2008</anticipatedstartdate>
    <actualstartdate>8/09/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>25/05/2010</actualenddate>
    <samplesize>525</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Mark Nidorf</primarysponsorname>
    <primarysponsoraddress>3/140 Mounts Bay Rd
Perth 6000
Western Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>Mark Nidorf</fundingname>
      <fundingaddress>3/140 Mounts Bay Rd
Perth 6000
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Heart Care Western Australia.</fundingname>
      <fundingaddress>3/140 Mounts Bat Rd
Perth
Western Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Heart Research Institute of Western Australia</fundingname>
      <fundingaddress>Sir Charles Gairdner Hospital
Verdun St 
Nedlands</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Heart Research Institute of Western Australia</sponsorname>
      <sponsoraddress>Queen Elizabeth II Hospital
Nedlands
Perth 6009
Western Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>John Eikelboom</sponsorname>
      <sponsoraddress>Henderson Reseach Centre
McMaster University
711 Concession Street 
Hamilton, Ontario 
Canada 
L8V 1C3</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Prospective Randomized Observer Blinded Evaluation trial to determine the effect of adding colchicine 0.5mg/d to usual medical therapy in patients with proven coronary disease on the risk of future coronary events and stroke [unrelated to atrial fibrillation or intra-cranial hemorrhage]</summary>
    <trialwebsite>N/A</trialwebsite>
    <publication>Presented AHA November 2012

Published
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. J Am Coll Cardiol.
2012 Dec 13. SO735-1097(12)05478-2. JACC Jan 13
</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Queen Elizabeth II Hospital</ethicname>
      <ethicaddress>Verdun St
Nedlands, 6009
Perth
Western Australia</ethicaddress>
      <ethicapprovaldate>1/07/2008</ethicapprovaldate>
      <hrec>2008-001</hrec>
      <ethicsubmitdate>1/02/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Mark Nidorf</name>
      <address>3/140 Mounts Bay Rd
Perth 6000
Western Australia</address>
      <phone>+61413145410</phone>
      <fax>+61 8 93211012</fax>
      <email>smnidorf@gmail.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Nidorf</name>
      <address>3/140 Mounts Bay Rd
Perth 6000
Western Australia</address>
      <phone>+61413145410</phone>
      <fax>+61 8 93211012</fax>
      <email>smnidorf@gmail.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Nidorf</name>
      <address>3/140 Mounts Bay Rd
Perth 6000
Western Australia</address>
      <phone>+61413145410</phone>
      <fax>+61 8 93211012</fax>
      <email>smndorf@gmail.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Mark Nidorf</name>
      <address>Heart Care Western Australia
3/140 Mounts Bay Rd
Perth 6000 
Western Australia</address>
      <phone>+61413145410</phone>
      <fax>+61 8 93211012</fax>
      <email>smnidorf@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>